Finally, a number of in vitro studies in hepatoma cells have revealed that TGF-β treatment may either dampen the expression of Id1 or induce the expression of CXXC5 transcription factors to promote TGF-β signaling and suppress cancer cell proliferation [76,77]. The gene discussed is CXXC5; the disease is hepatocellular carcinoma.